UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Makes New $906,000 Investment in Pharvaris (NASDAQ:PHVS)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in Pharvaris (NASDAQ:PHVS - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 48,896 shares of the company's stock, valued at approximately $906,000.

A number of other institutional investors also recently modified their holdings of PHVS. Sofinnova Investments Inc. grew its holdings in Pharvaris by 2.9% during the 2nd quarter. Sofinnova Investments Inc. now owns 601,534 shares of the company's stock valued at $11,309,000 after buying an additional 16,862 shares in the last quarter. Deerfield Management Company L.P. Series C boosted its position in shares of Pharvaris by 31.6% in the second quarter. Deerfield Management Company L.P. Series C now owns 1,397,279 shares of the company's stock valued at $26,269,000 after acquiring an additional 335,687 shares during the period. Finally, Novo Holdings A S boosted its position in shares of Pharvaris by 47.7% in the second quarter. Novo Holdings A S now owns 1,725,000 shares of the company's stock valued at $32,430,000 after acquiring an additional 556,970 shares during the period.

Wall Street Analysts Forecast Growth

Separately, Oppenheimer increased their target price on shares of Pharvaris from $38.00 to $42.00 and gave the stock an "outperform" rating in a research note on Friday, September 6th.

Pharvaris Trading Up 2.9 %

NASDAQ PHVS traded up $0.56 on Friday, hitting $19.57. The company's stock had a trading volume of 97,070 shares, compared to its average volume of 88,885. The firm has a market cap of $623.11 million, a P/E ratio of -6.99 and a beta of -3.17. Pharvaris has a 52-week low of $15.37 and a 52-week high of $33.00. The company's 50-day simple moving average is $21.22 and its 200 day simple moving average is $19.22.

Pharvaris Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.